Superficial urinary bladder carcinoma

Summary

Superficial urinary bladder carcinoma (MONDO:0004200) is a cancer and 18 clinical trials. Top therapeutic interventions include mitomycin, hyaluronidase (human recombinant), and porfimer sodium. A subtype of urinary bladder carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 18

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	superficial urinary bladder carcinoma
Mondo ID	MONDO:0004200
DOID	DOID:7371
NCIT	C27474
SNOMED CT	425231005
UMLS	C1336527
MedGen	234371
Is cancer (heuristic)	yes

Also known as: superficial bladder cancer · superficial bladder carcinoma · superficial urinary bladder cancer · superficial urinary bladder carcinoma

Disease family

This is a subtype of urinary bladder carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › urinary system disorder › urinary bladder disorder › urinary bladder neoplasm › urinary bladder cancer › urinary bladder carcinoma › superficial urinary bladder carcinoma

Related subtypes (8): bladder adenocarcinoma, bladder squamous cell carcinoma, bladder urachal carcinoma, urinary bladder small cell neuroendocrine carcinoma, stage IVb bladder cancer, bladder transitional cell carcinoma, childhood bladder carcinoma, bladder small cell carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 18.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	5
PHASE1/PHASE2	4
PHASE3	3
Not specified	3
PHASE2/PHASE3	1
EARLY_PHASE1	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00816075	PHASE2/PHASE3	UNKNOWN	Efficacy of Distilled Water Versus Mitomycin C on Preventing Recurrences of Bladder Cancer After Transurethral Resection
NCT01149174	PHASE3	COMPLETED	Preoperative Intravesical Electromotive Mitomycin-c for Primary Non-muscle Invasive Bladder Cancer
NCT02106572	PHASE3	TERMINATED	Therapeutic Instillation of Mistletoe
NCT02773849	PHASE3	COMPLETED	ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)
NCT03379909	PHASE2	RECRUITING	Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer
NCT04752722	PHASE1/PHASE2	RECRUITING	LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
NCT00191711	PHASE2	COMPLETED	Intravesical Gemcitabine Instillation Followed by Transurethral Resection for the Treatment of Patients With Superficial Bladder Cancer at Low Risk.
NCT00192049	PHASE2	COMPLETED	A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer
NCT00322699	PHASE1/PHASE2	COMPLETED	Sequential Whole Bladder Photodynamic Therapy (WBPDT) in the Management of Superficial Bladder Cancer
NCT00595088	PHASE2	COMPLETED	Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer
NCT01687244	PHASE2	COMPLETED	Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer
NCT01939756	PHASE1/PHASE2	COMPLETED	Intravesical Natural Baobab Oil in the Management of BCG-induced Lower Urinary Tract Symptoms
NCT02007005	PHASE1/PHASE2	COMPLETED	Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer
NCT00782587	PHASE1	COMPLETED	Study of Immediate Post-Operative Intravesical Instillation of Chemophase® in Patients With Superficial Bladder Cancer
NCT00734994	EARLY_PHASE1	COMPLETED	Mitomycin C With Hyperthermia and Intravesical Mitomycin C to Treat Recurrent Bladder Cancer
NCT03091764	Not specified	COMPLETED	Evaluation of a Patient-Reported Symptom Index for NMIBC
NCT03121768	Not specified	UNKNOWN	A New Prognostic Model for Predicting the Outcome of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
NCT05084586	Not specified	UNKNOWN	Comparison of the Efficacy and Safety of Continuous and Single-Dose Intravesical Epirubicin Instillation

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
MITOMYCIN	4	3
HYALURONIDASE (HUMAN RECOMBINANT)	4	1
PORFIMER SODIUM	4	1
WATER	4	1
NADOFARAGENE FIRADENOVEC	3	1
CHEMBL4071382	0	3
CHEMBL5175144	0	3
CHEMBL5429422	0	1
PROTOPORPHYRIN DISODIUM	-1	1